206 related articles for article (PubMed ID: 14666698)
1. Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation.
Srinath P; Rao PN; Knaus EE; Suresh MR
Anticancer Res; 2003; 23(5A):3923-8. PubMed ID: 14666698
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors.
Praveen Rao PN; Amini M; Li H; Habeeb AG; Knaus EE
J Med Chem; 2003 Nov; 46(23):4872-82. PubMed ID: 14584938
[TBL] [Abstract][Full Text] [Related]
3. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and structure-activity relationship studies of 3,4,6-triphenylpyran-2-ones as selective cyclooxygenase-2 inhibitors.
Rao PN; Uddin MJ; Knaus EE
J Med Chem; 2004 Jul; 47(16):3972-90. PubMed ID: 15267236
[TBL] [Abstract][Full Text] [Related]
5. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
Patel MI; Subbaramaiah K; Du B; Chang M; Yang P; Newman RA; Cordon-Cardo C; Thaler HT; Dannenberg AJ
Clin Cancer Res; 2005 Mar; 11(5):1999-2007. PubMed ID: 15756026
[TBL] [Abstract][Full Text] [Related]
6. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines.
Waskewich C; Blumenthal RD; Li H; Stein R; Goldenberg DM; Burton J
Cancer Res; 2002 Apr; 62(7):2029-33. PubMed ID: 11929821
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of N-acetyl-2-(or 3-)carboxymethylbenzenesulfonamides as cyclooxygenase isozyme inhibitors.
Chen QH; Rao PN; Knaus EE
Bioorg Med Chem; 2005 Aug; 13(15):4694-703. PubMed ID: 15914011
[TBL] [Abstract][Full Text] [Related]
8. The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone.
Gamradt SC; Feeley BT; Liu NQ; Roostaeian J; Lin YQ; Zhu LX; Sharma S; Dubinett SM; Lieberman JR
Anticancer Res; 2005; 25(1A):107-15. PubMed ID: 15816526
[TBL] [Abstract][Full Text] [Related]
9. COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro.
Mohseni H; Zaslau S; McFadden D; Riggs DR; Jackson BJ; Kandzari S
J Surg Res; 2004 Jun; 119(2):138-42. PubMed ID: 15145695
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective inhibitors.
Khanapure SP; Garvey DS; Young DV; Ezawa M; Earl RA; Gaston RD; Fang X; Murty M; Martino A; Shumway M; Trocha M; Marek P; Tam SW; Janero DR; Letts LG
J Med Chem; 2003 Dec; 46(25):5484-504. PubMed ID: 14640557
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effects of Cox-1 and -2 inhibition on bladder and prostate cancer in vitro.
Farivar-Mohseni H; Kandzari SJ; Zaslau S; Riggs DR; Jackson BJ; McFadden DW
Am J Surg; 2004 Nov; 188(5):505-10. PubMed ID: 15546559
[TBL] [Abstract][Full Text] [Related]
12. In vitro antiproliferative activity against human colon cancer cell lines of representative 4-thiazolidinones. Part I.
Ottanà R; Carotti S; Maccari R; Landini I; Chiricosta G; Caciagli B; Vigorita MG; Mini E
Bioorg Med Chem Lett; 2005 Sep; 15(17):3930-3. PubMed ID: 15993594
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro.
Ohneseit PA; Krebiehl G; Dittmann K; Kehlbach R; Rodemann HP
Radiother Oncol; 2007 Feb; 82(2):229-38. PubMed ID: 17207548
[TBL] [Abstract][Full Text] [Related]
14. Resistance of prostate cancer cell lines to COX-2 inhibitor treatment.
Wagner M; Loos J; Weksler N; Gantner M; Corless CL; Barry JM; Beer TM; Garzotto M
Biochem Biophys Res Commun; 2005 Jul; 332(3):800-7. PubMed ID: 15907789
[TBL] [Abstract][Full Text] [Related]
15. 3-(2-Methoxytetrahydrofuran-2-yl)pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors.
Ranatunge RR; Earl RA; Garvey DS; Janero DR; Letts LG; Martino AM; Murty MG; Richardson SK; Schwalb DJ; Young DV; Zemtseva IS
Bioorg Med Chem Lett; 2004 Dec; 14(24):6049-52. PubMed ID: 15546727
[TBL] [Abstract][Full Text] [Related]
16. The effects of cyclooxygenase-2 inhibitors on urological cancer cells.
Yoshimura R; Matsuyama M; Kawahito Y; Takemoto Y; Tsuchida K; Kuratsukuri K; Segawa Y; Shinnka T; Sano H; Nakatani T
Int J Mol Med; 2004 Jun; 13(6):789-93. PubMed ID: 15138613
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of a novel class of rofecoxib analogues as dual inhibitors of cyclooxygenases (COXs) and lipoxygenases (LOXs).
Chen QH; Rao PN; Knaus EE
Bioorg Med Chem; 2006 Dec; 14(23):7898-909. PubMed ID: 16904331
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1).
Vona-Davis L; Riggs DR; Jackson BJ; McFadden DW
J Surg Res; 2004 Jun; 119(2):143-8. PubMed ID: 15145696
[TBL] [Abstract][Full Text] [Related]
19. COX-2 inhibition and cancer: experimental findings and clinical correlates.
Roberts EG; Vona-Davis L; Riggs DR; Jackson BJ; Hohseni H; Kandzari SJ; McFadden DW
W V Med J; 2004; 100(3):96-101. PubMed ID: 15384741
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.
Rao PN; Chen QH; Knaus EE
J Med Chem; 2006 Mar; 49(5):1668-83. PubMed ID: 16509583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
